A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity

Summary

This study is a randomized, double-blind, placebo-controlled, parallel phase 2 study to evaluate efficacy, safety, pharmacokinetic characteristics and immunogenicity of TG103 injection for weight management in non-diabetic patients with overweight in the presence of comorbidities or obesity, in addition to lifestyle intervention.

Timeline

Start

2024-02-21

Primary completion

2024-09-26

Completion

2024-10-24

Drugs

Indications